CYP.AX - Cynata Therapeutics Limited
| Previous close | 0.1500 |
| Open | 0.1450 |
| Bid | 0.1400 x 1582700 |
| Ask | 0.1500 x 3535900 |
| Day's range | 0.1450 - 0.1450 |
| 52-week range | 0.1300 - 0.4450 |
| Volume | |
| Avg. volume | 231,111 |
| Market cap | 26.047M |
| Beta (5Y monthly) | 0.70 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0700 |
| Earnings date | 22 Aug 2023 - 28 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireDimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor
Dimension Inx, a biomaterials platform company developing therapeutics that restore tissue and organ function, announced today the appointments of Paul K. Wotton, Ph.D., to the board of directors and Chris Ehrlich as Senior Advisor.
Simply Wall St.We're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Simply Wall St.
We Think Shareholders Are Less Likely To Approve A Pay Rise For Cynata Therapeutics Limited's (ASX:CYP) CEO For Now
The underwhelming share price performance of Cynata Therapeutics Limited ( ASX:CYP ) in the past three years would have...
PR NewswireLUMC to Fund New Clinical Trial of Cynata's Cymerus™ MSCs in Kidney Transplantation
Cynata Therapeutics Limited (ASX: "CYP" or "Cynata"), a clinical-stage biotechnology company specialising in cell therapeutics, is delighted to announce that the LUMC is funding an important clinical trial to investigate Cynata's Cymerus™ MSCs as a treatment for renal graft rejection and to potentially reduce the requirement for anti-rejection drugs.
- Simply Wall St.
Here's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...